

Stockholm, 1 December 2011

Correction of previous press release

In the English version of the press release “Sobi holds Capital Markets Seminar” dated 29 November, 2011, the gross margin for the Specialty Distribution Portfolio was incorrectly stated as <40%. The correct figure is <50%, see table below. The Swedish version of the press release was correct.

Product area	Revenues	Growth	Gross margin, %
ReFacto®	608	34%	>60%
Core Products	803	6%	~60%
Specialty Distribution Portfolio	459	8%	<50%

Revenues are rolling 12 months as of 30 September 2011 in reported exchange rates, adjusted for discontinued products. Growth figures are based on YTD 9 months 2011, adjusted for currency and discontinued products.

For further information, please contact:

Åsa Stenqvist, Head of Communications and Investor Relations
Tel.: +46 8 697 21 88

Swedish Orphan Biovitrum (Sobi)

Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the health of rare disease patients and their families. The product portfolio comprises about 60 marketed products as well as projects in the late clinical phase. Key therapeutic areas are Inflammation and Genetics & Metabolism. In 2010 Sobi had revenues of SEK 1.9 billion and around 500 employees. The share (STO: SOBI) is listed on OMX NASDAQ Stockholm. More information is available at www.sobi.com.

The information above has been published pursuant to the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on 1 December 2011 at 12.30 CET.